Halozyme Therapeutics, Inc. (NASDAQ:HALO) SVP Michael J. Labarre Sells 1,697 Shares of Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) SVP Michael J. Labarre sold 1,697 shares of the business’s stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $58.28, for a total transaction of $98,901.16. Following the completion of the sale, the senior vice president now directly owns 173,756 shares of the company’s stock, valued at $10,126,499.68. This represents a 0.97 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Halozyme Therapeutics Stock Down 0.4 %

Shares of HALO opened at $57.70 on Friday. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14. The company has a 50-day moving average price of $54.08 and a two-hundred day moving average price of $54.71. The stock has a market cap of $7.11 billion, a price-to-earnings ratio of 16.82, a P/E/G ratio of 0.42 and a beta of 1.25. Halozyme Therapeutics, Inc. has a 12 month low of $37.73 and a 12 month high of $65.53.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, beating the consensus estimate of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The business had revenue of $298.01 million for the quarter, compared to analyst estimates of $285.74 million. Equities analysts predict that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Hedge Funds Weigh In On Halozyme Therapeutics

Large investors have recently modified their holdings of the stock. Congress Asset Management Co. lifted its stake in Halozyme Therapeutics by 446.5% in the third quarter. Congress Asset Management Co. now owns 2,433,579 shares of the biopharmaceutical company’s stock valued at $139,298,000 after buying an additional 1,988,238 shares during the period. Norges Bank acquired a new stake in shares of Halozyme Therapeutics in the 4th quarter valued at about $60,054,000. Capital World Investors bought a new stake in shares of Halozyme Therapeutics in the fourth quarter worth $35,773,000. Arrowstreet Capital Limited Partnership grew its holdings in shares of Halozyme Therapeutics by 141.3% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 992,887 shares of the biopharmaceutical company’s stock valued at $47,470,000 after acquiring an additional 581,475 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. increased its position in shares of Halozyme Therapeutics by 171.2% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 831,414 shares of the biopharmaceutical company’s stock worth $39,750,000 after purchasing an additional 524,802 shares during the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Wells Fargo & Company lowered their target price on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. HC Wainwright raised their price objective on Halozyme Therapeutics from $70.00 to $72.00 and gave the company a “buy” rating in a research note on Wednesday, February 19th. Piper Sandler upped their target price on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research report on Friday, January 10th. JMP Securities lifted their price target on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research report on Friday, November 1st. Finally, Benchmark reaffirmed a “buy” rating and set a $75.00 price objective on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Four analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $62.78.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.